Background. Acute deterioration of renal function is an important side-effect of angiotensin-converting enzyme (ACE) inhibitors, especially if accompanied by other nephrotoxic events. Angiotensin II receptor 1 blockers (ARB) are thought to have fewer side-effects on renal perfusion and function. We examined the effects of valsartan (VAL) on kidney function as well as the contribution of the nitric oxide (NO) system in a rat model of ischaemic acute renal failure (ARF). Methods. ARF was induced by 40 min of clamping of both renal arteries in female Sprague±Dawley rats. Renal haemodynamic and tubular parameters were determined during post-ischaemic infusion of vehicle, VAL, VAL and the NO-synthase substrate L-arginine, and VAL together with inhibition of NO synthases (NOS) by L-NMMA. Results. Clamping induced acute renal failure with marked decreases in glomerular ®ltration rate (GFR) and renal plasma¯ow (RPF) accompanied by a rise in renal vascular resistance (RVR) and fractional sodium excretion. Valsartan caused a slight but signi®cant improvement of GFR and RPF without full recovery of renal function and caused a lowering of RVR and tubular sodium loss. L-arginine-co-administration had no additive bene®cial effect. Valsartan-induced changes were not signi®cantly depressed by unspeci®c inhibition of NOS. Conclusions. Inhibition of the angiotensin II-receptor 1 diminishes the deleterious effects of ischaemia and reperfusion on glomerular function and on the renal microcirculation. An involvement of the NO system could not be demonstrated.
Introduction
Drugs that in¯uence the renin±angiotensin system are used with increasing frequency in the treatment of chronic renal, heart, and vascular disease. A wellknown side-effect of angiotensin-converting enzyme (ACE) inhibition is acute worsening of renal function due to the predominant dilatation of the efferent arterioles and consequent decrease in glomerular ®ltration w1x. The effects of angiotensin II-receptor 1 blockers (ARB) on renal function and perfusion parameters are less well described. In bilateral renalartery stenosis w2x and after kidney transplantation w3x, ARB administration caused renal functional impairment. However, in anaesthetized rats, two different selective ARB caused increases in both glomerular ®ltration rate (GFR) and cortical plasma¯ow w4x. In volume-depleted rats, ARB caused lesser reductions in vascular resistance in efferent arterioles than ACE inhibitors while preserving single-nephron GFR w5x. Heller et al. w6x observed a bene®cial effect of preischaemic ARB administration in a rat model of acute renal failure. In healthy humans a single dose of candesartan caused an increase in effective renal plasmā ow (RPF) without changes in GFR w7x, whereas losartan reduced GFR up to 50% after volume depletion w8x. Also, after uninephrectomy and subsequent arti®cial stenosis of the remaining renal artery of dogs, reductions in systemic blood pressure due to losartan as well as captopril were accompanied by acute decreases in renal blood¯ow and glomerular ®ltration w9x. Taken together, ARB may have different effects on renal haemodynamics depending on the state of hydration and the kind of pre-existing renal damage.
Over the last ten years, tight interactions between angiotensin II (Ang) and nitric oxide (NO) in the regulation of renal perfusion and function have been described. In isolated perfused afferent arterioles of the rabbit, Ang effects depended on the presence or absence of NO w10x. Administration of ARB reduced the decrease in renal blood¯ow following NO-synthase inhibition in rats w11x, while inhibition of NOS reduced the rise in GFR induced by infusion of losartan, at least in spontaneously hypertensive rats w12x.
At present it is not known how kidney perfusion and function change both during and after acute ischaemic renal failure, especially when ARBs are given during this vulnerable phase. We therefore examined whether acute angiotensin II-receptor blockade by valsartan causes improvement of renal perfusion in rats with acute renal failure (ARF). Results from these studies may help to determine when to continue or begin ARB in human ARF. Furthermore, we examined the involvement of the NO-system in the effects caused by ARB infusion.
Material and methods

Drugs
L-arginine (L-Arg) and N-monomethyl-L-arginine (L-NMMA) were purchased from Sigma (Deisenhofen, Germany); FITC inulin was ordered from Bio¯or (Uppsala, Sweden) and sodium-para-aminohippurate (PAH) from Merck, Sharpe & Dohme (West Point, USA). Valsartan (VAL) was kindly provided by Novartis Pharma (Wehr, Germany).
Four groups of animals consisting of eight rats each were investigated: control animals were treated with Ringer saline as vehicle; the VAL group was treated with valsartan 12.5 mgu kguh, the VALuL-Arg group was given valsartan 12.5 mgukguh combined with L-Arg 500 mgukguh; and the VALuL-NMMA group was given valsartan 12.5 mgukguh in combination with L-NMMA 1.0 mgukguh.
Valsartan for intravenous infusion was prepared according to manufacturer's instructions: the drug was dissolved in 0.1 N potassium hydroxide and titrated to a neutral pH with hydrochloric acid. Valsartan dosage was determined from previous ®ndings in anaesthetized animals (data not shown); the highest dose with no signi®cant effect on systemic blood pressure was chosen for this study.
Dosages of L-Arg and L-NMMA were chosen from previous studies in clamping-induced ARF showing only slight changes on blood pressure following infusion of these substances w13x.
Experimental procedure
Female Sprague±Dawley rats (Charles River, Sulzfeld, Germany; ns32, weight 242"11 g) with free access to water and standard rat chow prior to the experiments were used. Animals were housed with a regular 12 h-light-darkcycle under steady temperature, pressure and humidity conditions, according to the regulations of the German Tierschutzgesetz as well as the NIH principles of laboratory animal care. Anaesthesia was induced by thiobutabarbital 100 mgukg i.p., which lasts for the entire duration of the experiment. The animals were placed on a thermoregulated heating table to maintain body temperature at 37.58C. A tracheostomy with insertion of an endotracheal tube was performed to allow spontaneous breathing. Thereafter, the left femoral vein was cannulated with a PE 50 catheter (Portex, Hythe, UK) for constant infusion of Ringer lactate at 2 mluh for replacement of¯uid and electrolyte losses and for administration of drugs. The infusion rate of Ringer lactate was chosen from previous experiments w13x to avoid dehydration and activation of the renin±angiotensin system. A second PE 50-catheter was placed in the left femoral artery for continuous measurement of arterial blood pressure using a pressure transducer (Hellige, Freiburg, Germany) and for blood collection. The urinary bladder was catheterized with a PE 10-catheter inserted through a suprapubic incision for monitoring urinary¯ow and for collection of urine samples. A bilateral horizontal¯ank incision was then performed and both renal pedicles were prepared; the renal arteries were gently divided from the venae renales. After completion of surgery, a bolus of 3 mg¯uorescence-marked inulin together with 2 mg paraaminohippurate in 2 ml of isotonic saline was slowly administered intravenously, followed by a continuous infusion of both substances (1.5 mluh).
After an equilibration period of 30 min the protocol shown in Figure 1 was initiated. Directly after the baseline sampling-period, both renal arteries were clamped for 40 min and venous out¯ow was not inhibited. A subsequent resting period was then followed by 120 min of drug infusion.
Each urine collection period, indicated by the dark-shaded bar in Figure 1 , lasted 20 min, and a corresponding blood sample (300 ml each) was drawn after 10 min and immediately centrifuged. For all collection periods, inulin clearances and PAH clearances were calculated for estimation of GFR and RPF respectively. At the same time, mean arterial blood pressure was recorded. Renal blood¯ow (RBF) was calculated as: RBFsRPFu(1±haematocrit). Renal vascular resistance (RVR) was computed by the formula: RVRs MAPuRBF. Haematocrit was measured by a Technicon H1-analyser (Bayer Diagnostics, Wiesbaden, Germany).
Analytical procedures
Inulin concentrations were determined by¯uorescence spectrometry using an LS-50 luminescence-spectrometer (Perkin±Elmer, U È berlingen, Germany), and PAH concentrations by spectrometry at 550 nm using a microplate reader (Molecular Devices, Crawley, UK). Sodium concentrations in serum and urine were measured by¯ame photometry (Autoanalyzer FCM 6341, Eppendorf, Hamburg, Germany). 
Statistical analyses
Results are presented as means"SEM. The normal distribution of all mean values was checked by the Kolgomorow± Smirnow test. Two-way ranked ANOVAs with repeated measurements and two-sided Student's t-tests, as appropriate, were used for statistical analysis. A P value O0.05 was considered statistically signi®cant. Analyses were done using SPSS 6.1 for Windows (SPSS GmbH, Mu È nchen, Germany).
Results
Results from the entire study are summarized in Table 1 . Mean arterial blood pressure was not different between the four experimental groups before the infusion period. VAL signi®cantly decreased MAP compared with control during the infusion period (77"8 mmHg vs 96"11 mmHg; Ps0.02) and compared with VALuL-NMMA from infusion (Ps0.002) until the end of the experiment. From clamping onwards, MAP declined in all groups except the VALuL-NMMA-group, in which the NO-synthase antagonist stabilized MAP over time.
Urine volume ( Figure 2 ) rose in all groups following the clamping procedure and corresponded to the induction of acute polyuric renal failure. Immediately after clamping, increases of up to eight times baseline urinary volumes were observed, followed by a slow decrement in urine excretion in the control group. A similar decrease was followed by stabilization in the VAL group and further increases of urinary volumes in VALuL-Arg and VALuL-NMMA during drug infusion.
The increase during L-Arg co-administration was statistically signi®cant compared with control and VAL during drug infusion and thereafter. In the control group, urine volume returned almost to baseline levels at about 17 mlumin by the end of the experiment.
Glomerular function was directly determined by FITC-inulin clearance. As shown in Figure 3 , baseline GFR during the 50-min equilibration period was about 1.4 mlumin in all groups. Clamping induced a steep decline in GFR, resulting in values that were 10±15% of baseline, with no differences between experimental groups. Valsartan with and without co-administration of L-Arg or L-NMMA caused a small but signi®cant rise in GFR during the infusion period, which was also detectable after cessation of drug infusion. However, GFR never returned to baseline. No signi®cant differences were observed between the three groups. RPF was measured by PAH clearance. Similarly to GFR, RPF rapidly decreased after induction of renal ischaemia. RPF decreased from baseline values of 5.5 mlumin to very low levels of 0.22 mlumin (control) and 0.47 mlumin (VAL and VALuL-Arg). At this time, no signi®cant differences could be detected between the groups. Infusion of valsartan alone led to an increase in RPF, which, at the end of the experiment was signi®cantly higher than in control (Ps0.03). Coadministration of L-Arg with VAL caused a distinct increase in RPF especially during the infusion period, resulting in statistically signi®cant differences between control and VALuL-NMMA groups. Compared with the control groups, Valsartan caused increases in RPF that were independent of pharmacological interventions on the NO system ( Figure 4) . RVR was calculated from MAP and RBF, and the results are shown in Figure 5 . At baseline, RVR was about 1.0±1.7 kPauminuml in all groups. Clamping led to a 15-to 20-fold increase of RVR compared with baseline. After clamping, RVR increased further in control animals by up to 100-fold from baseline (with high SEM). VAL administration alone as well as with L-Arg and L-NMMA co-infusion blunted this increase from the beginning of drug infusion and thereafter. During the infusion period, L-Arg co-administered with VAL caused a signi®cant decrease in RVR that was prolonged to the end of the trial. In contrast, competitive NOS inhibition with L-NMMA slightly but signi®cantly increased RVR compared with VALuL-Arg.
Fractional sodium excretion (FE Na ) was calculated as a marker for tubular function. Clamping induced a steep rise in FE Na in all groups, ranging from 32% in the VALuL-Arg group up to 46% in the control group. FE Na then decreased to about half the maximal values until the end of the experiment. There were no differences between the groups. Infusion of VAL caused reductions in FE Na that were independent of changes in the NO system.
Discussion
The aim of this study was to describe the haemodynamic effects of intravenous administration of the ARB valsartan after induction of renal ischaemia. Our model of acute ischaemic renal failure was the clamping of both renal arteries for 40 min. Renal dysfunction in this study was characterized by an acute and persistent fall in renal blood¯ow, a concordant depression of GFR, an increase of ®ltration fraction indicating the involvement of post-glomerular vasoconstriction in this form of ARF, and a rise in renal vascular resistance without signi®cant changes in systemic arterial blood pressure. After releasing the clamps, urine volume increases due to ischaemic tubular changes with loss of proximal and distal tubular reabsorption capacity were observed and were characterized by increases in FE Na in the control group. This pattern of ARF has been previously described by our group w13x.
Valsartan infused for 2 h after induction of warm ischaemia to the kidneys led to a slight but signi®cant improvement in renal function. The dose of valsartan was chosen from preliminary experiments showing no effects on systemic blood pressure following ARB infusion. In the present experiments, a small decline in MAP was observed, making it impossible to rule out systemic effects on renal perfusion and function. However, decreases in perfusion pressure should not cause increases in RPF and GFR, as was seen in the VAL group.
These observations con®rm results from other groups. Ang receptors 1 have been observed in both afferent and efferent arterioles of C57BL6 mice, and Ang dose-dependently constricted both vessels in a similar fashion w14x. This vasoconstriction was completely abolished by the selective ARB, CV-11974. In healthy animals under anaesthesia, two different ARB increased cortical blood¯ow and GFR w4x. In hypertensive human volunteers, Buter et al. w7x demonstrated positive effects of candesartan on effective RPF and ®ltration fraction. These effects were independent of decreases of systemic blood pressure and renal function before the treatment, which was impaired in some of the 17 patients reported.
In a previous study, clamping of the renal pedicle increased intrarenal Ang levels measured by radioimmunoassay w15x. Losartan treatment at the time of reperfusion resulted in a signi®cant decrease in serum creatinine 72 h after ischaemia, indicating a role for Ang and renal Ang receptors 1 in renal perfusion after ischaemiaureperfusion injury. However, renal haemodynamics and function were not measured directly in this study w15x. In our study during the ®rst 3 h of reperfusion, VAL increased renal blood¯ow to a greater extent than GFR, resulting in a decreasing ®ltration fraction, and lowered RVR compared with control. This indicates a protective effect of VAL on ischaemic renal tissue, but without the potential to reverse completely the circulatory changes induced by the clamping procedure. In addition, VAL decreased FE Na , which is in contrast to reports of ARB actions on tubular function in healthy animals.
Xie et al. w16x observed an increased natriuresis due to blockade of Ang receptors 1 in the proximal tubules. In the case of reperfusion, improvement of renal blood ow with concurrent increases in medullary perfusion seem to prevail over the direct effects of ARB on the proximal tubular epithelium, resulting in a net decrease in renal sodium loss.
The bene®t of VAL on renal perfusion in the current study could be explained simply by the blockade of Ang receptors 1 . However, as another possibility, the effects may be mediated at least partly by the unopposed activation of Ang receptors 2 by excessive Ang. This may lead to a secondary vasodilatation due to the production of vasoactive substances such as NO, bradykinin, or prostaglandins w17x. Our experimental approach cannot rule out these secondary effects of ARBs.
In a previous study using a similar model of acute warm ischaemia we showed a bene®cial effect of L-Arg infusion as substrate of NO synthases on renal function and perfusion w13x. Administration of L-Arg for 60 min increased GFR two-to threefold compared to controls. L-Arg also improved renal function in other models of acute renal failure, including contrastmedia-induced w18x or cyclosporin-induced ARF w19x. L-Arg in these studies was postulated to enhance production of vasoactive NO by NO synthases in ischaemic tissue thereby improving microperfusion in these areas. Tome Â et al. w20x showed bene®cial effects of acute NOS activation on GFR and tubular integrity and function 2 days after clamping the renal arteries. However, L-Arg given together with Ang-receptor 1 blockade showed no additive effect on GFR or RPF, whereas a non-signi®cant trend for lower RVR was observed. Together, these data show that simultaneous infusion of the indirect vasodilating agent and ARB after ischaemia and during initial reperfusion showed no additional bene®t on renal function compared to VAL alone.
We additionally looked for a possible involvement of the NO system in the effects of VAL on renal function. Therefore, L-NMMA, a non-selective competitive antagonist of NO synthases, was infused simultaneously with ARB. We have previously demonstrated that inhibition of NOS during reperfusion after clamping did not improve GFR and abolished the bene®cial effects of L-Arg in this setting w13x. Tome Â et al. w20x demonstrated a deleterious effect of L-NAME, an alternative non-selective NOS inhibitor, on GFR, an increase in serum urea, and a distinct rise in renal sodium loss 2 days after ischaemiaureperfusion injury. Madrid et al. w21x administered valsartan after L-NAME-treatment and observed a reversal of the negative effects of NOS inhibition on RBF and GFR in anaesthetized rats. The same was true for cortical renal blood¯ow reported by the same group w22x. The authors concluded that Ang-receptor 1 blockade reduced renal vasoconstriction induced by NOSinhibition and that renal cortical perfusion in the anaesthetized rat is modulated by NO interacting with Ang.
Administration of L-NMMA together with VAL during ARF led to non-signi®cant decreases in RPF and GFR when compared with VAL alone. During infusion, RVR increased slightly more than in the VAL group although the dose of L-NMMA used was suf®cient to completely reverse the effects of direct NOSactivation with L-Arg w13x. Two explanations are possible in this situation of grossly disturbed renal perfusion and function. Either the bene®cial effects of Ang-receptor 1 blockade surpass the described modulation of renal cortical perfusion by the NO system, or unopposed stimulation of Ang-receptor 2 subtypes accounts for the production of vasodilatory compounds which could not be blocked by the present dose of L-NMMA.
Urine output was distinctly higher during concomitant L-Arg and L-NMMA together with VAL compared with control and VAL alone; however, this was signi®cant only during infusion of L-Arg. We could not demonstrate any signi®cant changes in FE Na amongst the groups. Therefore the increase in urinary volumes could not be attributed to renal sodium loss. A diuretic effect of NOS antagonists has not been described previously and could not explain our data. We observed an increase in urine production that was probably not related to the NO-system. The volume of the substitution solution did not differ between the groups, and pressure diuresis seems an unlikely explanation. One explanation could be an osmotic effect of amino acids; however, this has not been observed before, and urine osmolality was not examined in this series of experiments.
In summary, Ang-receptor 1 blockade with valsartan improved renal haemodynamics after warm ischaemiaureperfusion injury. The contribution of the NO system to this bene®cial effect is minor. A secondary involvement of the NO system due to the activation of Ang receptors 2 cannot be ruled out in the present studies.
